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Broadly cross-reactivemonoclonal antibodies define
epitopes for vaccine development against HIV and
other highly mutable viruses. Crystal structures are
available for several such antibody-epitope com-
plexes, but methods are needed to translate that
structural information into immunogens that re-elicit
similar antibodies. We describe a general computa-
tional method to design epitope-scaffolds in which
contiguous structural epitopes are transplanted to
scaffold proteins for conformational stabilization
and immune presentation. Epitope-scaffolds de-
signed for the poorly immunogenic but conserved
HIV epitope 4E10 exhibited high epitope structural
mimicry, bound with higher affinities to monoclonal
antibody (mAb) 4E10 than the cognate peptide, and
inhibited HIV neutralization by HIV+ sera. Rabbit
immunization with an epitope-scaffold induced anti-
bodies with structural specificity highly similar to
mAb 4E10, an important advance toward elicitation
of neutralizing activity. The results demonstrate that
computationally designed epitope-scaffolds are
valuable as structure-specific serological reagents
and as immunogens to elicit antibodies with prede-
termined structural specificity.
INTRODUCTION
A protective HIV vaccine, or a universal flu vaccine, likely will
elicit antibodies that block infection of diverse circulating strains
of HIV or influenza. Several anti-HIV antibodies with broad
neutralizing reactivities have been isolated from natural infection,
and approximately 25% of HIV-1-infected individuals produce
broadly neutralizing sera (for review, see Stamatatos et al.,1116 Structure 18, 1116–1126, September 8, 2010 ª2010 Elsevier Lt2009), but efforts to elicit such responses by vaccination have
failed. Anti-influenza broadly neutralizing antibodies (bNAbs)
also have been characterized (Kashyap et al., 2008; Okuno
et al., 1993; Sui et al., 2009; Throsby et al., 2008), but the annual
influenza vaccine elicits potent neutralizing antibodies only
against the vaccine strains and closely related isolates.
The anti-HIV mAb 4E10 neutralizes 98% of HIV strains (Binley
et al., 2004); hence, elicitation of 4E10-like antibodies is a major
goal for HIV vaccine design. 4E10 binds a contiguous epitope
in the membrane proximal external region (MPER) of gp41 just
N-terminal to the transmembrane domain (Stiegler et al., 2001;
Zwick et al., 2001), an epitope that is likely only transiently
exposed during viral fusion with the target cell (Frey et al.,
2008). Nuclear magnetic resonance structural analysis of
MPER peptides in lipid micelles found a kinked helix partially
embedded in lipid (Sun et al., 2008). Crystal structures of mAb
4E10 in complex with gp41 peptides revealed that 4E10 binds
to a helical epitope in an end-on manner with the N terminus
and one face of the helix docked into a hydrophobic cavity on
the antibody; the bound epitope adopts a short 3/10 helix fol-
lowed by an alpha helix, and conserved HIV side chains from
both regions make significant antibody contacts (Cardoso
et al., 2005, 2007; Scherer et al., 2010; Xu et al., 2009). The
antibody also has a long, hydrophobic complementarity-
determining region H3 (CDR H3) loop, which does not bind
directly to the helical epitope but which may provide contacts
to the viral lipid membrane and contribute to neutralization
(Cardoso et al., 2005, 2007; Scherer et al., 2010; Xu et al.,
2009). Here, as a first step to elicit antibodies with the binding
and neutralizing properties of mAb 4E10, we aimed to develop
immunogens that would elicit antibodies with the exact binding
specificity of mAb 4E10 for its core peptide epitope.
A major hurdle confronting 4E10-vaccine design is that the
epitope is naturally poorly immunogenic. While 4E10-like activity
has been detected in HIV+ patients with broadly neutralizing
activity, the frequency is low (5%) (Binley et al., 2008; Li
et al., 2009; Sather et al., 2009). Furthermore, previous attempts
to elicit 4E10-like antibodies by vaccination using solubled All rights reserved
Figure 1. Models of 4E10 Fv/Epitope-Scaffold Complexes
The helical 4E10 epitope (yellow) was transplanted from the 4E10 Fab/gp41
peptide complex (boxed at top left) onto different scaffold proteins (red).
Structure
Computational Design of 4E10 Epitope-Scaffoldstrimeric gp140 (Derby et al., 2006), VLP-membrane-anchored
gp41 variants (Kim et al., 2007), or a gp120 construct with the
4E10 epitope embedded in the highly immunogenic V2 loop
(Law et al., 2007), failed to elicit reactivity against the epitope
primary sequence. MPER peptides anchored to liposomes or
hepatitis B surface antigen particles have elicited modest
responses against 4E10 peptides (Phogat et al., 2008; Watson
and Szoka, 2009), but whether these responses were directed
to the 4E10 epitope or other epitopes was not determined. In
none of these cases was the helical epitope conformation
necessarily stabilized, though in all cases the antigens did bind
to mAb 4E10.
Crystallographic analysis of several anti-HIV (Calarese et al.,
2003; Cardoso et al., 2005; Ofek et al., 2004; Zhou et al., 2007)
and anti-influenza (Ekiert et al., 2009; Sui et al., 2009) bNAb/
epitope complexes, combined with advances in computational
protein design (Kuhlman et al., 2003), provides new opportuni-
ties for structure-based vaccine design (Dormitzer et al., 2008).
Here, we pursued a strategy of stabilizing an epitope in its
antibody-bound conformation, and presenting that stabilized
epitope in an immunogenic format, in order to elicit antibodies
with structural specificity similar to the target antibody. Specifi-
cally, we engineered ‘‘epitope-scaffold’’ immunogens in which
the HIV 4E10 epitope was transplanted by computational design
to small, nonviral scaffold proteins for conformational stabiliza-
tion and presentation to the immune system without the immu-Structure 18, 1116–11nodominant variable regions typical of persistent pathogens.
The computational design methods are general and should be
applicable for structural stabilization of a variety of contiguous
epitopes of different conformations from HIV, influenza, and
other viruses.
RESULTS
Computational Design of Epitope-Scaffolds
We designed a total of 103 4E10 epitope-scaffolds by the side-
chain grafting method (models representative of the variety of
scaffold topologies are shown in Figure 1). This method entailed
‘‘matching’’ and ‘‘design’’ stages. In the automated ‘‘matching’’
stage, a subset of the Protein Data Bank (PDB) (Berman et al.,
2000) was exhaustively searched for scaffold proteins with
a surface-exposed backbone segment similar in conformation
to the 4E10 epitope (NWFDITxxLW in PDB ID: 2FX7; Cardoso
et al., 2007). The resulting ‘‘hits’’ were filtered first by backbone
clash with the antibody and second by antibody-epitope binding
energy (epitope side chains were transferred to the scaffold
and energy minimization (Gray et al., 2003) was used to optimize
antibody and epitope side-chain conformations as well as the
antibody-scaffold rigid-body orientation). Scaffolds selected in
the ‘‘matching’’ stage were taken to the semiautomated design
stage in which amino acids were designed for scaffold positions
outside the epitope. The design stage aimed to ensure scaffold
stability and solubility, avoid additional interactions between
scaffold and antibody, support the optimized epitope side-chain
conformations, eliminate undesired functional sites, and trim
extraneous domains.
‘‘Validated’’ Epitope-Scaffolds Are Stable
and Bind mAb 4E10 with High Affinity
Epitope-scaffolds were expressed in Escherichia coli, purified by
immobilized metal affinity chromatography and size-exclusion
chromatography (SEC), and screened for 4E10 Fv binding in
qualitative SEC assays. Constructs were validated if they ex-
pressed as soluble protein (not within inclusion bodies) and
were purifiable to stable, soluble species that bound Fv by
SEC; nonvalidated constructs were eliminated from further
consideration. A total of 135 constructs were tested for expres-
sion (103 designs plus 32 purification tag variants), and, of those,
24 different designs (23% of 103 designs) were carried forward
for quantitative analysis of mAb-binding by surface plasmon
resonance (SPR). Biophysical data are collected in Table 1 for
the representative set of 10 validated 4E10 epitope-scaffolds de-
picted in Figure 1, and background information on each scaffold
is provided in Table S1 (available online).
To facilitate interpretation of mAb 4E10-binding experiments,
the epitope-scaffold solution multimer state and stoichiometry
of Fv-binding were assessed by static light scattering (SLS)
and SEC. Examples of SEC data are given in Figure S1. Solution
multimer state and Fv-binding stoichiometry accorded with
expectation (monomer and 1:1, or dimer and 2:2 for T18) for
5 of 12 epitope-scaffolds (T18, T36, T93, T161, T278). The
other epitope-scaffolds formed unexpected multimers that
dissociated in the presence of Fv, suggesting that multimers
self-associating through the hydrophobic 4E10 epitope were in
equilibrium with rare monomers. Aggregation was noted26, September 8, 2010 ª2010 Elsevier Ltd All rights reserved 1117
Table 1. Solution Properties of 4E10 Epitope-Scaffolds
Epitope-Scaffold Solution Multimer State Tm (C)
Fv:Epitope-Scaffold
Binding Stoichiometry
Interaction Parameters (SPR)
Analyte: 4E10 Fv Ligand: Epitope-Scaffolda Analyte: Epitope-Scaffold Ligand: 4E10 IgGb
kOFF/kON (nM) kON (M
-1s-1) kOFF (s
-1) kOFF/kON (nM) kON (M
-1s-1) kOFF (s
-1)
T18 Dimer R100 2:2 Low Specific
Activityc
Low Specific
Activityc
Low Specific
Activityc
2.75 1.47 3 105 4.05 3 104
T36 Monomer 44 1:1 0.014 5.89 3 106 8.34 3 105 0.044 1.95 3 106 8.59 3 105
T88 Tetramer 64 2:2 5.6 1:4.0 3 105
2:2.24 3 102
1:4.8 3 102
2:1.1 3 103
0.047 3.94 3 106 1.87 3 104
T93 Monomer 79 1:1 0.0075 6.98 3 106 5.23 3 105 0.028 3.17 3 106 8.73 3 105
T117 Dimer 56 1:1 Low Specific
Activityc
Low Specific
Activityc
Low Specific
Activityc
%0.01d – –
T161 Monomer 65 1:1 0.015 7.92 3 106 1.15 3 104 0.11 3.10 3 106 3.43 3 104
T163 Monomer, dimer 72 Multiple species 0.263 2.57 3 106 6.75 3 104 ND ND ND
T176 Monomer, dimer 48 Multiple species 0.14 4.49 3 106 6.18 3 104 0.051 6.44 3 106 3.26 3 104
T246 Monomer, dimer, trimer 62 1:1 3.3 1:2.34 3 106
2:3.06 3 103
1:1.66 3 102
2:2.62 3 103
ND ND ND
T278 Monomer 51 1:1 0.89 1:3.13 3 106
2:1.72 3 102
1:3.2 3 102
2:1.63 3 103
1.85 3.71 3 105 6.84 3 104
Italicized values: SPR data were fit using a two-state interaction model; the second on-rate has units of sec-1. ND: experiment not performed. For all reported values, standard error is% ±3 of the last
significant figure.
a Epitope-scaffold was immobilized by direct amine-coupling on CM5 chip or by biotinylation and capture on SA chip.
b 4E10 IgG was captured by amine-coupled anti-human IgG.
cCoupling epitope-scaffold to chip results in an inactive surface, likely due to lysine residues neighboring the epitope.
d Stated value is an upper limit on the KD; off-rate was too slow to fit kinetics.
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Figure 2. Crystallographic Analysis of 4E10 Epitope-Scaffolds
(A) Crystal structures of six epitope-scaffolds (cyan tubes) superimposed with design models (red tubes), with the epitope region colored yellow. Four structures
are unliganded and two are complexed with 4E10 Fv W(H100A)A (H-chain, light blue; L-chain, magenta). Resolution of structures was 2.3 (T18, PDB ID: 3LEF),
2.0 (T161, PDB ID: 3LF9), 1.9 (T117, PDB ID: 3LF6), 2.5 (T246, PDB ID: 3LG7), 2.65 (T88-Fv, PDB ID: 3LH2), and 2.8 (T93-Fv, PDB ID: 3LHP) A˚.
(B) Epitope structure (yellow tubes and sticks) from each of the epitope-scaffold crystal structures, superimposed with the 4E10 Fab-bound structure of a gp41
peptide (green tube and sticks) from PDB ID 2FX7 (Cardoso et al., 2007). Backbone rmsd values between epitope-scaffold and peptide are indicated for each
superposition.
Structure
Computational Design of 4E10 Epitope-Scaffoldspreviously for gp120 with engrafted MPER sequences (Law
et al., 2007). Multimerization of some 4E10 epitope-scaffolds
will be addressed in detail in a separate manuscript (H.X., M.C.
Clifton, M.A.H., Della J. Friend, T. B.-H., J.F.B.-J., J. Burgner,
L.S., and R.K.S., unpublished data).
Epitope-scaffold affinities for mAb 4E10 were generally quite
high. Antibody binding affinity and kinetics were assessed by
SPR in two formats: with 4E10 Fv in solution as ‘‘analyte’’ and
epitope-scaffolds coupled to the sensor chip as ‘‘ligand’’ (to
assess interactions without avidity), and with 4E10 IgG captured
on the chip and epitope-scaffold in solution (to allow avidity).
Examples of SPR data and fits are shown in Figure S2, and
conditions for each SPR experiment are given in Table S2.
With epitope-scaffolds on the chip, equilibrium dissociation
constants (KD) ranged from 8 pM to 6 nM, and all epitope-
scaffolds bound 4E10 Fv more tightly than 4E10 peptides
(KD = 10–20 nM) (Brunel et al., 2006; Xu et al., 2009), gp41
(KD = 32–35 nM) (Klein et al., 2009) or gp140 trimers from isolate
SF162 (KD = 130 nM) (Xu et al., 2009). The range of KDs was
similar with epitope-scaffolds as analytes (22 pM to 3 nM).
Monomeric epitope-scaffolds exhibited similar KDs in both
formats, while 120-fold tighter binding due to bivalent avidity
was detected for T88 (KD = 47 pM versus 5.6 nM) and 2.7-fold
tighter binding was detected for T176 (KD = 51 pM versus
140 pM), consistent with stoichiometry data. In both formats,
variations in both kon and koff contributed to variations in KD.
Epitope-scaffolds showed a range of thermal stabilities
assessed by circular dichroism temperature melt analysis
(Tm = 44
C to Tm R 100C), though a majority (60%) were veryStructure 18, 1116–11stable with Tm > 60
C, and a large majority (80%) were stable
with Tm > 50
C.
Crystallographic Analyses Reveal High Epitope
Structural Mimicry by 4E10 Epitope-Scaffolds
To assess epitope structural mimicry, crystal structures were
determined for six different epitope-scaffolds, four of unliganded
epitope-scaffolds, and two of complexes with a 4E10 Fv
construct biochemically validated elsewhere (Xu et al., 2009)
(Figure 2). Crystallization conditions are in Table S3; X-ray
diffraction and refinement statistics are in Table 2; stereo images
of electron density maps are given in Figure S3.
The overall conformations of the epitope-scaffolds agreedwell
with design models in five of six cases (Figure 2A), with back-
bone rmsd values between models and structures of 0.47,
0.50, 0.79, 1.14, and 1.26 A˚ for epitope-scaffolds T117, T18,
T246, T93, and T161, respectively. The structure of the T88-Fv
complex revealed an unintended domain-swapped dimer
binding two Fv molecules, consistent with the 2:2 stoichiometry
measured by SEC and SLS. Nevertheless both T88-Fv
complexes were very similar to the design model; ignoring two
residues that bridge the T88 dimer, backbone rmsd between
the two Fv-monomer complexes and the model were 0.6 and
0.5 A˚, respectively.
Most importantly, epitope mimicry was excellent in both
Fv-bound and unbound epitope-scaffolds (Figure 2B). Back-
bone rmsd between epitope-scaffold and the 4E10-bound con-
formation of the gp41 peptide (Cardoso et al., 2007), computed
over epitope residues 672–680, was 0.99, 0.31, 0.99, and 1.1 A˚26, September 8, 2010 ª2010 Elsevier Ltd All rights reserved 1119
Table 2. X-Ray Diffraction Data and Refinement Statistics for the Epitope-Scaffold Structures
T18 T88-Fv T93-Fv T117 T161 T246
Data Collection
Space group P6522 P21 P212121 P212121 C2221 P212121
Cell dimensions 56.4, 56.4,
324.1 A˚
75.9, 145.9,
78.6 A˚; 92.5
53.0, 88.6,
150.0 A˚
49.2, 82.0,
94.2 A˚
40.7, 75.4,
79.6 A˚
91.6, 94.9,
108.4 A˚
Resolution (A˚)a 48.30–2.30
(2.38–2.30)
28.01–2.65
(2.74–2.65)
29.54–2.70
(2.80–2.70)
49.21–1.90
(1.97–1.90)
32.64–2.00
(2.07–2.00)
28.82–2.50
(2.59–2.50)
Number observed reflectionsa 115,705 (8910) 190,285 (17,961) 66,868 (4874) 133,236 (12,691) 38,309 (2008) 150,445 (12,033)
Number unique reflectionsa 13,770 (1304) 49,017 (4883) 19,356 (1705) 30,053 (2886) 8462 (755) 33,220 (3180)
Redundancya 8.40 (6.83) 3.88 (3.68) 3.45 (2.86) 4.43 (4.40) 4.53 (2.66) 4.53 (3.78)
Completeness (%)a 93.7(91.5) 98.9 (98.6) 96.2 (85.5) 97.5 (95.2) 98.3 (89.9) 99.5 (96.8)
Rmergea 0.086 (0.373) 0.095 (0.376) 0.102 (0.405) 0.057 (0.341) 0.052 (0.185) 0.107 (0.429)
Average I/s (I)a 9.0 (3.9) 9.4 (2.7) 7.1 (2.2) 17.2 (2.6) 18.6 (4.0) 6.6 (2.0)
Structure Refinement
Resolution (A˚) 46.78–2.30 26.70–2.65 28.99–2.70 31.50–1.90 27.37–2.00 28.82–2.50
Rwork/Rfree 0.258/0.290 0.222/0.270 0.243/0.335 0.223/0.279 0.204/0.260 0.257/0.301
Number of atoms
Protein 1275 9019 5112 2494 925 3155
Water 55 132 82 262 127 94
Other 4 (1 ethylene
glycol)
— 4 (1 ethylene
glycol)
15 (3 phosphates) — 55 (11 sulfates)
Rmsd from ideal values
Bond lengths (A˚) 0.009 0.006 0.009 0.009 0.011 0.014
Bond angles () 1.146 0.927 1.132 1.056 1.004 1.189
Chiral volume (A˚3) 0.070 0.054 0.051 0.061 0.057 0.062
Ramachandran plot statistics
Most favored regions (%) 95.8 90.4 90.0 94.1 100.0 99.4
Additional allowed regions (%) 3.5 9.2 9.6 5.9 0.0 0.6
Generously allowed regions (%) 0.0 0.0 0.0 0.0 0.0 0.0
Disallowed regions (%) 0.7 (1 res.b) 0.4 (4 res.c) 0.3 (2 res.c) 0.0 0.0 0.0
Estimated coordinate error
(maximum likelihood e.s.u.) (A˚)
0.19 0.240 0.17 0.137 0.208
Average B factor
Protein 66.4 57.2 68.1 43.6 45.1 76.6
Water 58.6 49.7 49.6 49.7 50.9 73.7
Other 85.3 53.2 82.4 96.3
a Values in parentheses correspond to the highest resolution shell.
b Residue 129, which is in a gturn conformation, as is the 1.5 A˚ resolution parent structure 1Z6N.
c Fv light chain residue 52 (51 by Kabat numbering) of all four chains, which is in a highly conserved g-turn conformation.
Structure
Computational Design of 4E10 Epitope-Scaffoldsfor the unbound structures of T18, T117, T161, and T246 respec-
tively, 0.16 A˚ for each monomer in the T88-Fv complex, and
0.31 A˚ in the T93-Fv complex. B-factor analysis indicated that
the epitope backbones were generally as well ordered as the
epitope-scaffolds overall (Figure S4). Side-chain mimicry was
reduced in the unliganded structures (Figure 2B), but high affin-
ities for Fv indicated that appropriate side-chain conformers
were attainable. Indeed, intermolecular contacts within the
unliganded crystals stabilized different epitope side-chain
conformations at some positions (Figure S5). The T88-Fv and
T93-Fv complexes demonstrated precise mimicry at the side-
chain level, with all-atom epitope rmsd of 0.48 and 0.36 A˚,
respectively; these complexes reproduced nearly all atomic1120 Structure 18, 1116–1126, September 8, 2010 ª2010 Elsevier Ltcontacts across the bNAb-peptide interface (Cardoso et al.,
2005, 2007; Xu et al., 2009) but made some additional contacts
(Tables S4–S6 and Figure S6).
Epitope-Scaffolds as Reagents Reveal That Neutralizing
Activity in HIV+ Sera Has 4E10-Like Helical Specificity
While Nonneutralizing Antipeptide Sera Does Not
Sather et al. (2009) recently found evidence for the presence of
4E10-like antibodies in the serum of one HIV+ individual
(‘‘VC10028’’). Support for this finding came primarily from the
fact that a 4E10 peptide, but not a scrambled 4E10 peptide,
could inhibit a fraction of the neutralizing activity of this serum
in an in vitro neutralization assay. There are many potentiald All rights reserved
Figure 3. 4E10 Epitope-Scaffolds Inhibit
Neutralizing Activity in HIV+ SerumVC10028
(A and B) Neutralization of JR-FL pseudovirus by
serial dilutions of serum VC10028 (Sather et al.,
2009) in the absence (open diamonds) or presence
(solid shapes) of different 4E10 epitope-scaffolds
at a concentration of 10 mg/ml epitope-scaffolds.
All epitope-scaffolds partially inhibit the neutral-
izing activity except a ‘‘dead-epitope’’ epitope-
scaffold (X36, blue inverted triangles in B). Data
are representative of three separate experiments;
error bars represent means ± SD.
Structure
Computational Design of 4E10 Epitope-Scaffoldsantibody epitopes on the 4E10 peptide, especially given that the
peptide likely samples many different conformations in solution,
so the precise structural epitope(s) of the neutralizing antibodies
in serum VC10028 could not be identified. Having demonstrated
epitope structural mimicry crystallographically (Figure 2), we em-
ployed 4E10 epitope-scaffolds as reagents to determine
whether the epitope conformation stabilized on the scaffolds
was a target of the cross-neutralizing antibodies in VC10028.
Several epitope-scaffolds inhibited the neutralizing activity of
the sera (Figures 3A and 3B), but no inhibition was detected by
a ‘‘dead-epitope’’ version of one scaffold (X36) in which the
‘‘WF’’ of the epitope was mutated to ‘‘ED’’ (Figure 3B). These
results demonstrated that neutralizing antibodies targeting the
helical epitope structure targeted by mAb 4E10 were present
in the VC10028 sera. In contrast, nonneutralizing rabbit sera eli-
cited by a 4E10 peptide-KLH conjugate had no significant affinity
for any of several epitope-scaffolds tested, even though the
peptide-KLH sera bound avidly to 4E10 peptide itself
(Figure 4A). This result demonstrated that while the 4E10
peptide-KLH conjugate was immunogenic (one of three rabbits
produced peptide-specific antibodies), it did not elicit antibodies
with structural specificity similar to 4E10. Indeed, comparison ofFigure 4. Structural Specificities of bNAb 4E10 and Anti-4E10 Peptide Rabbit Serum Are Dram
(A) ELISA of antipeptide serum binding to 4E10 peptide and different epitope-scaffolds. Data are the averag
(B) ELISA of antipeptide serum binding to alanine mutant 4E10 peptides. Data are the average of three expe
(C) ELISA of bNAb 4E10 binding to alanine mutant 4E10 peptides. Data are the average of three experiment
Structure 18, 1116–1126, September 8, 2010 ªpeptide-KLH sera and mAb 4E10 binding
to ala-scanned peptides (Bianchi et al.,
2005) (Figures 4B and 4C) confirms that
the specificities are very different; mAb4E10 binding is greatly diminished by mutants W672A, F673A,
T676A, and L679A that remove critical contacts in the mAb/
peptide crystal structure (Cardoso et al., 2005, 2007; Xu et al.,
2009), but peptide-KLH sera binding to those mutants is
undiminished. Together, these results showed how epitope-
scaffolds may be useful as reagents to identify the presence or
absence of precise structural specificities in sera and implied
that epitope-scaffolds will be useful as ‘‘bait’’ to isolate anti-
bodies targeting predefined structural epitopes.
An Epitope-Scaffold Elicited a Structurally Specific
Antiepitope Response
The fact that the 4E10-like antibodies in serum VC10028 had
structural specificity similar to mAb 4E10, while nonneutralizing
antibodies in peptide-KLH sera did not, suggested that
neutralization via the 4E10 epitope may require antibodies with
4E10-like structural specificity, and underscored the importance
of testing epitope-scaffolds for their ability to re-elicit such
structural specificity. To this end, we carried out immunization
experiments with specific endotoxin-free preparations of one
4E10 epitope-scaffold (T88). Two groups of three rabbits were
immunized with T88, one group with QS21 as adjuvant, andatically Different
e of two experiments.
riments.
s.
2010 Elsevier Ltd All rights reserved 1121
Figure 5. ELISA Binding of Anti-T88 Rabbit Sera to gp41 in Presence
of Peptide and Epitope-Scaffold Competitors
Anti-T88 sera from two rabbits (blue, PEI adjuvant, five immunizations; red,
QS21 adjuvant, six immunizations) binds to gp41 (‘‘Sera alone’’). Addition of
peptide (‘‘Sera+peptide’’) or different scaffolds (‘‘Sera+T161,’’ ‘‘Sera+T163,’’
‘‘Sera+T36’’) significantly reduces gp41vbinding, but addition of a ‘‘dead-
epitope’’ epitope-scaffold (‘‘Sera+X36’’) does not. ELISA response of prebleed
rabbit sera to gp41 was subtracted from the data. Data were averaged from
two or four experiments; error bars represent means ± SD.
Structure
Computational Design of 4E10 Epitope-Scaffoldsthe other with PEI. One animal from each group developed
antibodies that bound to HXB2 gp41, and this gp41-reactivity
was inhibited by wild-type 4E10 peptide, demonstrating specific
reactivity to the 4E10 epitope sequence (Figure 5). Further, the
gp41-reactivity of the anti-T88 polyclonal sera from these two
rabbits was inhibited by three different epitope-scaffolds tested
(T36, T161, and T163) but not by a ‘‘dead-epitope’’ version of the
T36 epitope-scaffold (Figure 5), demonstrating specific reactivity
to the helical structure of the 4E10 epitope stabilized on the
scaffolds.
To assess the fine specificities of the anti-T88 polyclonal
sera and mAb 4E10 across the helical epitope, we measured
the binding of both sera and mAb to alanine-substituted 4E10
peptides using a multiplexed Luminex assay (Opalka et al.,
2003). The results are displayed in Figure 6 as ‘‘relative avidity’’
in which the avidity for each ala mutant is divided by the avidity
of mAb 4E10 for the wild-type peptide. A relative avidity signifi-
cantly less than 1.0 indicates engagement of a particular side
chain, as mutations to alanine should not detract from peptide
helical propensity. Strikingly, the results indicated that both
T88 sera strongly engaged most epitope side chains trans-
planted onto the T88 scaffold, as relative avidities for alamutants
at gp41 positions 672–675 (WFDI) and L679 were less than 0.3
(p < 0.03 in all cases except sera2 at I675 where relative avidity
was less than 0.4 with p = 0.02). Two transplanted epitope side
chains (T676 andW680) were engaged by one of the sera but not
both; T676 relative avidity was 0.33 ± 0.28 for sera1 (engaged
with relative avidity < 0.7, p = 0.02) but 1.61 ± 0.33 for sera2,
and W680 relative avidity was 0.49 ± 0.21 for sera2 (engaged
with relative avidity < 0.8, p = 0.01) but 0.74 ± 0.50 for sera1.
Relative avidities for mAb 4E10 showed a similar overall pattern
of side-chain engagement, except that mAb 4E10 did not
engage I675 (relative avidity, 1.35 ± 0.18) and did strongly
engage T676 (relative avidity, 0.08 ± 0.05). The data for mAb1122 Structure 18, 1116–1126, September 8, 2010 ª2010 Elsevier Lt4E10 agreed with previous competitive ELISA experiments
(Brunel et al., 2006) except at positions 675 and 680 where
Luminex indicated no mAb engagement but competitive ELISA
(Brunel et al., 2006) indicated moderate engagement. As ex-
pected, neither of the two T88 sera nor mAb 4E10 had signifi-
cantly altered avidity for ala mutations of gp41 residues N677
and W678 that are located on the opposite face of the helix
from theWFDITxxLW epitope of 4E10 and were not transplanted
onto the T88 scaffold.
Gp41-specific IgG was purified from the anti-T88 polyclonal
sera and tested for fine specificity and neutralization. The fine
specificity of the gp41-specific IgG was consistent with that of
the sera in Figure 6. Neither the sera nor purified and concen-
trated anti-gp41 IgG reproducibly neutralized HIV-1 in an
in vitro neutralization assay (not shown).
DISCUSSION
Here, we presented a new technique, computational design of
epitope-scaffolds, to design immunogens that preserve the
structure of a conserved epitope and expose that structure on
a variety of different protein scaffolds with different immunologic
backgrounds. We transplanted a conserved HIV epitope to
multiple non-HIV proteins and succeeded to produce small,
stable, soluble proteins with high affinity for the target mono-
clonal (KDs < 1 nM). Indeed, several epitope-scaffolds bound
mAb 4E10 up to 1000-fold more strongly than cognate peptide
(KD 10 pM for epitope-scaffolds versus 10 nM for peptide).
Crystal structures of multiple scaffolds demonstrated near
perfect mimicry of the desired epitope backbone conformation
(rmsd %1 A˚). We demonstrated the utility of epitope-scaffolds
as serologic reagents to identify the presence or absence of
antibodies targeting specific structural epitopes; this diagnostic
utility conceptually extends to the use of epitope-scaffolds as
‘‘bait’’ for isolating such antibodies from libraries. Most impor-
tantly, we demonstrated that antibodies specific for the helical
structure and the conserved side chains of the 4E10 epitope
could be elicited by immunization with one such 4E10 epitope-
scaffold. In contrast, immunization with peptide-KLH failed to
elicit this desired specificity, and previous studies showed that
several different constructs competent for 4E10 binding failed
to elicit any detectable reactivity to the 4E10 linear sequence
(Derby et al., 2006; Kim et al., 2007; Law et al., 2007). This
example suggests the potential power of epitope-scaffolding;
with the technique described here, many types of contiguous
epitopes could be transplanted onto scaffolds for structural
stabilization and immune presentation, and epitope-structure-
specific immune responsesmight be further enhanced by glycan
or PEG masking of the scaffold, by multimeric, oriented display
of epitope-scaffolds on particles, by heterologous prime-boost
immunizations, or combinations thereof. We also note that the
epitope-scaffold concept is not limited to scaffolding of antibody
epitopes, it could also prove useful to study, or design inhibitors
for, peptide-protein and protein-protein interactions.
To our knowledge, the antibodies elicited by T88 are the first
induced by vaccination to possess structural specificity highly
similar to that of 4E10. This is an important advance for HIV
vaccine design, because the helical specificity possessed by
4E10 and also the neutralizing sera in VC10028 (Sather et al.,d All rights reserved
Figure 6. Luminex Analysis of bNAb 4E10 and
Anti-T88 Rabbit Sera Binding to Ala-Scanned
gp41 Peptides on Beads
Relative avidity for bNAb 4E10 (black) and two different
anti-T88 rabbit sera (blue, PEI adjuvant; red, QS21 adju-
vant) quantifies the avidity of each antibody/peptide or
antisera/peptide pair relative to bNAb 4E10 binding to
wild-type 4E10 peptide. Both anti-T88 antisera exhibit
low relative avidity for mutants W672A, F673A, D674A,
I675A, and L679A, which indicates that the antisera
strongly engaged the 4E10 side chains at those positions
on the helical epitope. Data were averaged from five
experiments each run in duplicate; error bars represent
mean ± SD.
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The T88 antisera elicited by these first-generation designs did
not neutralize HIV, however, indicating that helical specificity
and the engagement of the conserved side chains of the 4E10
peptide epitope may not be sufficient. This result is consistent
with recent studies demonstrating that specific hydrophobic
residues on the tip of the 4E10 CDRH3 are required for maximum
potency neutralization: alanine (Alam et al., 2009; Scherer et al.,
2010; Xu et al., 2009) and aspartic acid (Scherer et al., 2010)
substitutions at the tip do not significantly reduce gp41 or
epitope-peptide binding, but they do reduce both lipid binding
(Alam et al., 2009; Scherer et al., 2010; Xu et al., 2009) and the
extraction of the epitope from the membrane (Xu et al., 2009),
either mechanism potentially contributing to neutralization
potency. As mentioned above, the tip of the 4E10 CDRH3
does not contact the peptide epitope used as the basis of the
design of these first-generation epitope-scaffolds (Cardoso
et al., 2005, 2007; Xu et al., 2009); further, no contacts with the
CDRH3 tip are seen in Fv 4E10/epitope-scaffold complex
structures as this was not a design criteria. Next-generation
epitope-scaffolds incorporating higher order structural com-
plementarity, such as viral membrane lipid structures, will be
employed to improve on this approach.
In summary, we introduced a computational methodology
that allows the faithful transplantation of conformational
epitopes into distinct protein platforms and demonstrated that
this leads to the appropriate stimulation of humoral responses
to a conserved, but intrinsically poorly immunogenic viral
epitope. Epitope-scaffolds therefore expand the universe of
immunogens available for vaccine research. For the case of
4E10, computationally designed scaffolds can next be pre-
sented to the immune system in the context of lipid membrane
surfaces, in combination with specific adjuvants to elicit anti-
bodies with expanded recognition and neutralization properties.EXPERIMENTAL PROCEDURES
Computational Design of Epitope-Scaffolds
The automatedmatching and design stages of the side-chain grafting protocol
were implemented in the Rosetta (Das and Baker, 2008) modeling platform.Structure 18, 1116–1126, September 8,The matching stage exhaustively searched 13337 single
chains from the PDB (Berman et al., 2000) for backbone
similarity with the 4E10 epitope by computing rmsd
between residues 671–680 or 672–680 in PDB ID:2FX7
(Cardoso et al., 2007) and all possible protein segmentsusing matched-width sliding windows in the query scaffolds. All hits with
rmsd <1 A˚ (or rmsd/length <0.1) were retained if backbone clash with antibody
was less than 100 score units. Epitope side chains were transferred to all-
glycine versions of the remaining hits, and then interfacial side-chain torsions
and the rigid-body orientation of antibody and epitope-scaffold were opti-
mized by minimization (Gray et al., 2003). Highly conserved epitope side
chains W672, F673, I675, L679, and W680 were transplanted to all scaffolds.
At moderately variable epitope positions (671, 674, 676), the most energeti-
cally favorable of the common HIV side chains was generally transplanted
(N, S, or G at 671; D, S, or N at 674; S or T at 676). Native scaffold side-chain
rotamers outside the epitope were recovered, and residues near (heavy atom
distance <4 A˚) the epitope or the antibody were designed, categorized as
‘‘intra’’ and ‘‘inter’’ positions, respectively. Inter residues were allowed to be
ALA, GLY, SER, and THR, and intra positions were allowed to be all amino
acids except CYS. Epitope-scaffolds were ranked by antibody binding energy
and human-guided design was performed on the best to a) revert unnecessary
or potentially destabilizing mutations; b) eliminate unpaired cysteines and
undesired functional sites; c) trim extraneous domains; and d) optimize solu-
bility. In two cases (T93 and T278), more advanced flexible backbone design
was performed for domain trimming (T93) or fusion to maltose binding protein
(MBP) for stabilization (T278); discussion of these methods is beyond the
scope of this manuscript and will be reported elsewhere (B.E.C. , Y.-E.A.B.,
D.J. Friend, K.E., H.X., E.B., T.B.-H., J.F.B.-J., L.S., R.K.S., and W.R.S.,
unpublished data).
Protein Expression, Purification, and Characterization
DNA segments encoding epitope-scaffold constructs were synthesized with
optimized codon usage and RNA structure (Codon Devices, Genscript
Corp.), subcloned into pET29 (EMD Biosciences), and transformed into
BL-21 Star E. coli (Invitrogen). Single colonies were expanded from starter
cultures in Luria Broth into ZYP-5052 autoinduction media (Studier, 2005)
plus kanamycin (100 mg/ml), incubated for 4 hr at 37C and then overnight
at 18C. Cultures were then pelleted and stored at 20C. Pellets were resus-
pended in standard buffer (50 mM Tris, 500 mM NaCl, 10 mM imidazole,
0.5 mg/ml lysozyme), sonicated on ice, and clarified by centrifugation. Super-
natants were tumbled with 10ml of nickel-NTA resin (SuperflowNTA, QIAGEN)
for 30 min at 4C. The resin was then rinsed twice with 10 mM imidazole, once
with standard buffer plus 20 mM imidazole and eluted with standard buffer
plus 250 mM imidazole. Eluates were concentrated by ultrafiltration (Amicon
Ultra, Millipore) and filtered through 0.22 mm Ultrafree-MC spin columns
(Millipore). Epitope-scaffolds were then purified by preparative size exclusion
chromatography (SEC) on Superdex 75 16/60 columns (GE Healthcare) at
room temperature in 25 mM PIPES (pH 7.0), 150 mM NaCl, 1 mM EDTA,
and 0.02% w/w sodium azide (PNEA). Epitope-scaffold purity was confirmed
by SDS-PAGE and analytical SEC; analytical SEC ± target NAb (Superdex 75
or 200 10/30 columns, GE Healthcare) in PNEA was used to assay qualitative2010 ª2010 Elsevier Ltd All rights reserved 1123
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Protein concentrations were determined with the BCA protein assay (Pierce);
solution thermostabilities (Tm) were determined by circular dichroism (CD)
spectroscopy with Jasco J-815 instrumentation as previously described (Xu
et al., 2009).
In order to prepare endotoxin-free protein for immunization studies, bacte-
rial pellets were alternately resuspended in detergent buffer (50 mMNaH2PO4,
500 mM NaCl, 10 mM imidazole, 0.5 mg/ml lysozyme, 0.01 mg/ml DNase,
0.1% Triton X114) and loaded IMAC resin was alternately initially washed in
10 mM imidazole, 50 mM NaH2PO4, 500 mM NaCl, 0.1% Triton X114.
Preparative SEC purification was carried out in sterile PBS on columns just
previously cleaned with a bolus of 1 M NaOH. Endotoxin levels were assayed
with the PyroGene Recombinant Factor C Endotoxin Detection System
(Lonza). Protein preparations were further purified using the ProteoSpin
Endotoxin Removal Maxi Kit (Norgen) if endotoxin levels exceeded 2EU/50
mg at a protein concentration of 1 mg/ml, the maximum level accepted for
immunization.
Crystallization and Crystallography
Crystals of epitope-scaffolds and epitope-scaffold-Fv complexes were grown
by vapor diffusion, under the conditions shown in Table S3. The complexes
were purified as such by SEC prior to crystallization. Diffraction data were
collected at170Con cryopreserved crystals, as detailed in Table 2, and pro-
cessed with d*TREK (Pflugrath, 1999). Initial structure factor phases were
determined by molecular replacement (search models in Table S3), using
the program Phaser (McCoy et al., 2007) or MolRep (Vagin and Teplyakov,
1997), as implemented under CCP4i (Potterton et al., 2003). Successive
rounds of modeling and positional and individual B factor refinement were
carried out with Coot (Emsley and Cowtan, 2004) and Refmac5 (Murshudov
et al., 1997). Five of the six structures were submitted to the TLSMD server
(Painter and Merritt, 2006a, 2006b) where TLS groups were defined. Structure
validation was carried out with Procheck (Laskowski et al., 1993), the MolPro-
bity server (Davis et al., 2007), and the RCSB ADIT validation server. The struc-
tures were deposited in the PDB (Berman et al., 2000) with accession codes in
Table S3. Data collection and structure refinement statistics are in Table 2.
Luminex Multiplex Assay
4E10 peptides with three lysines added to their C termini were amine-coupled
toBio-plex beads (Biorad,CA) (12mgpeptide/100 ml beads) asdescribedby the
manufacturer’s protocol. Serially diluted sera (pre- and postimmunization) or
mAb 4E10 were incubated with the bead cocktail for 1 hr at room temperature.
After four washes, beads were incubated with anti-rabbit or human PE-conju-
gated secondary Ab for 1 hr at room temperature. A final wash step was per-
formed prior to analysis on a Luminex 200 System (Invitrogen). Relative avidity
was computed by subtracting peptide-matched, prebleed mean fluorescent
intensity (MFI) from each sample MFI and then normalizing to the experi-
ment-matched MFI for bNAb 4E10 binding to wild-type 4E10 peptide.
Peptide ELISA
Binding of rabbit sera or bNAb 4E10 to 4E10 peptide (NWFDITNWLWYIRKKK)
(Derby et al., 2006), alanine mutant 4E10 peptides, and epitope-scaffolds was
assessed by ELISA as previously described (Derby et al., 2006).
Epitope-Scaffold Competitive ELISA
Rabbit sera (1:25) were incubated with epitope-scaffolds (100 mg/ml) for 1 hr,
and then the mixture was added to ELISA plates coated with recombinant
gp41 (HxB2) (0.5 mg/ml) (Meridian Life Science) for 90 min at 37C. The binding
of antibodies to gp41 was detected as above for the peptide ELISA.
Competing the Neutralizing Activity of HIV-1 + Sera
by Epitope-Scaffolds
Epitope-scaffolds were tested for their ability to inhibit the neutralizing activity
of plasma VC10028 as previously described for peptide inhibition (Sather et al.,
2009).
Immunizations
Rabbits were immunized monthly at the Pocono Rabbit Farm and Laboratory
Inc. (Canadensis, PA) with epitope-scaffolds mixed in PEI (Polysciences, Inc.)1124 Structure 18, 1116–1126, September 8, 2010 ª2010 Elsevier Ltor QS21 (Antigenics, Inc); 0.2 mg protein in 0.2 ml of PBS was administered
into the two hind legs (0.2 ml per injection site). KLH peptide immunizations
were performed by GenScript Corp (Piscataway, NJ); rabbits were immunized
with 0.5 mg KLH peptide and complete Freund’s adjuvant, and boosted at
weeks 2, 5, and 8 with 0.5 mg KLH peptide and incomplete Freund’s adjuvant.
KLH peptide sera were tested from day 0 and week 10.
Statistical Analyses
We performed statistical analyses using a one-tailed Student’s t test to ob-
tain p values on the significance of relative avidity levels below specified
thresholds.
ACCESSION NUMBERS
The crystal structures discussed in this paper were deposited in the PDB with
following codes: 3LEF (T18), 3LH2 (T88-Fv), 3LHP (T93-Fv), 3LF6 (T117), 3LF9
(T161), and 3LG7 (T246).
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Supplemental Information includes six figures and six tables and can be found
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